Compare Danaher Corporation (DHR) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs TORM plc — how do they compare? Danaher Corporation trades at $204.42 (market cap $145.83B), while TORM plc trades at $28.93 (market cap $2.93B). The key difference: Danaher Corporation is far larger — about 49.8× TORM plc's market cap, and TORM plc pays the higher dividend (9.77%). Which is the better fit depends on your goals.
| DHR | TRMD | |
|---|---|---|
Market Cap | $145.83B | $2.93B |
Sector | Health | Technology |
52-Week High | $242.05 | $34.87 |
52-Week Low | $161.91 | $18.77 |
Enterprise Value | $168.04B | $3.82B |
Dividend Yield | 0.77% | 9.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
TRMD trades at $29.04, down 0.51% today, with a bearish technical signal from moving averages but oversold RSI at 24.63. The company reported strong profitability with a 24.41% net margin and ROE of 15.62%, though Q1 2026 EPS missed expectations. Recent news highlights a major shareholder update from Oaktree Capital and a $0.70 dividend payment scheduled for June 2026.
Outlook remains positive with 100% analyst buy ratings, underpinned by robust cash flow and strategic positioning in tanker markets. Risks include earnings volatility and geopolitical impacts on freight rates, but valuation metrics like P/E of 8.4 suggest potential upside if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
